Could this be the secret to Pfizer's rebound strategy?

It could prove to be a case of better later than never for the healthcare giant.

Albert Bourla, Pfizer Chairman & CEO, addresses the current state of US vaccinations and the robust growth in Pfizer's ...

Pfizer is struggling right now, leaving it in the Wall Street doghouse; it won't be there forever.

These stocks offer high yields, are big names in their respective sectors, and have strong fundamentals.

Breaking news and analysis from time.com. Politics, world news, photos, video, tech reviews, health, science, and entertainment news.

Pfizer Inc. said an experimental drug failed to improve survival in patients with an advanced form of lung cancer that couldn ...

Passive income is the closest thing investors have to financial gravity. It pulls in money whether you are at your desk, on a ...

By Andrew Silver SHANGHAI, June 29 (Reuters) - GLP-1 drugs from Pfizer and Innovent Biologics have passed a preliminary ...

The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...

Everyone is still arguing about Novo Nordisk (NYSE:NVO | NVO Price Prediction), the Danish obesity juggernaut whose GLP-1 ...

Pfizer said on Thursday that finance chief Dave Denton will leave ⁠on August 15 to return to the consumer goods industry.